tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ASND Stock Latest News

Ascendis Pharma Gains UK Authorization for YORVIPATH
Company AnnouncementsAscendis Pharma Gains UK Authorization for YORVIPATH
10h ago
6K
ASND
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
PremiumPress Releases
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
11h ago
ASND
Ascendis Pharma A/S Outlines Financial Strategy
PremiumCompany Announcements
Ascendis Pharma A/S Outlines Financial Strategy
14d ago
6K
ASND
Ascendis Pharma Updates Share Capital Structure
PremiumCompany Announcements
Ascendis Pharma Updates Share Capital Structure
28d ago
6K
ASND
Ascendis, MoonLake Immunotherapeutics removed from Best Ideas List at Wedbush
PremiumThe Fly
Ascendis, MoonLake Immunotherapeutics removed from Best Ideas List at Wedbush
1M ago
ASND
MLTX
Ascendis Pharma price target raised to $260 from $196 at Wells Fargo
PremiumThe FlyAscendis Pharma price target raised to $260 from $196 at Wells Fargo
1M ago
ASND
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
PremiumPress Releases
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
2M ago
ASND
Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
PremiumMarket News
Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
3M ago
ASND
Ascendis Pharma price target raised to $225 from $207 at Wedbush
PremiumThe Fly
Ascendis Pharma price target raised to $225 from $207 at Wedbush
3M ago
ASND
Ascendis Pharma price target raised to $182 from $146 at Citi
PremiumThe Fly
Ascendis Pharma price target raised to $182 from $146 at Citi
3M ago
ASND
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
PremiumPress Releases
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
3M ago
ASND
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PremiumPress Releases
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
3M ago
ASND
Is ASND a Buy, Before Earnings?
PremiumPre-EarningsIs ASND a Buy, Before Earnings?
3M ago
ASND
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
PremiumPress Releases
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
3M ago
ASND
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
PremiumPress Releases
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
3M ago
ASND
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
PremiumPress Releases
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
3M ago
ASND
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
PremiumPress Releases
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
3M ago
ASND
Ascendis Pharma announces formation, launch with Frazier Life of Eyconis
PremiumThe Fly
Ascendis Pharma announces formation, launch with Frazier Life of Eyconis
3M ago
ASND
Ascendis Pharma price target raised to $156 from $133 at TD Cowen
PremiumThe Fly
Ascendis Pharma price target raised to $156 from $133 at TD Cowen
4M ago
ASND
Ascendis Pharma, Vector Pharma FZCO enter exclusive distribution agreement
PremiumThe FlyAscendis Pharma, Vector Pharma FZCO enter exclusive distribution agreement
4M ago
ASND
Ascendis Pharma Introduces Vision 2030
PremiumPress Releases
Ascendis Pharma Introduces Vision 2030
4M ago
ASND
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma
PremiumThe Fly
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma
4M ago
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >